Pulmonx Corporation

NASDAQ:LUNG

Medical - Devices

Healthcare
$2.69 +3.60%

+$0.05 today

Market cap
$117.15M
Beta
0.28
P/E (TTM)
-1.0
EPS (TTM)
-$1.27
52W Low $1.13High $3.88

Volume 0.48M

Average 0.44M

LUNG Debt Repayment

Cash used to repay borrowings during the period.

Pulmonx CorporationNASDAQ: LUNG

Debt Repayment · Q1 FY2026 · quarter ended Mar 2026

Debt repayment outflow grows to $1.79M

Q1 FY2026 debt repayment was $1.79M, compared with $0 a year earlier. Trailing-twelve-month debt repayment was $1.69M. Over 3 fiscal years it compounded at +4.8% a year.

Context

  • Debt repayment amounted to 0.1% of revenue in FY2025, unchanged from a year earlier.
  • Debt repayment increased in 1 of the last 3 fiscal years.
  • FY2025 was the lowest annual figure in the 4 fiscal years shown.

What to watch

Whether quarterly debt repayment holds near $1.79M or moves back toward the trailing-twelve-month quarterly average of $421.25K.

Sources:Cash FlowText generated from reported figures; not investment advice.

Latest quarterMar 2026
$1.79M+3600.0% QoQ
Last fiscal yearDec 2025
-$100K+5.3% YoY
LTMMar 2026
$1.69M+1873.7% YoY
Debt Repayment past and forecast growth by horizon
Horizon Past Forecast Difference
Quarter———
1 year+5.3%——
3-year CAGR+4.8%——
5-year CAGR——
10-year CAGR——

Debt Repayment history

USD · from the cash flow

Latest · FY2025
(100K) USD
Year-over-year change
-5.3%

Debt Repayment vs competitors

How LUNG compares with its peers on the latest reported figures

  • LUNG's LTM Mar 2026 debt repayment of $1.69M is the 3rd largest of the 10 companies compared; the peer median is $0.
  • Its year-over-year change of +1873.7% is the highest of 2, against a peer median of -100.0%.
  • Debt repayment amounts to 1.9% of revenue for LUNG, versus a peer median of 0.0%.
LUNG Competitors Peer median
Debt Repayment for LUNG and competitors
Company Period LTM YoY 3-year CAGR% of revenue
TELATELA Bio, Inc.LTM Jun 2026$14.03M —+11.9%17.6%
HYPRHyperfine, Inc.LTM Mar 2026$13.64M ——89.0%
LUNGPulmonx CorporationLTM Mar 2026$1.69M +1873.7%+4.8%1.9%
RLMDRelmada Therapeutics, Inc.LTM Mar 2026$0 ———
ASRTAssertio Holdings, Inc.LTM Mar 2026$0 ——0.0%
IMUXImmunic, Inc.LTM Mar 2026$0 ———
VXRTVaxart, Inc.LTM Mar 2026$0 ——0.0%
PMVPPMV Pharmaceuticals, Inc.LTM Mar 2026$0 ———
ACRVAcrivon Therapeutics, Inc. Common StockLTM Mar 2026$0 ———
TCRXTScan Therapeutics, Inc.LTM Mar 2026$0 -100.0%—0.0%
Peer median (excluding LUNG) $0-100.0%+11.9%0.0%

Competitors are the stored peer set for LUNG. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.

Cash Flow Statement

USD
Metric
FY2021
Dec 2021
FY2022
Dec 2022
FY2023
Dec 2023
FY2024
Dec 2024
FY2025
Dec 2025
Net Income(48.66M)(58.92M)(60.84M)(56.39M)(54M)
Depreciation & Amortization3.16M4M1.55M1.49M1.15M
Deferred Income Tax(6K)49K000
Stock-Based Compensation0022.1M22.96M0
Change in Working Capital(7.84M)(7.06M)(2.56M)(1.7M)(1.93M)
Accounts Receivables(2.43M)(2.19M)(3.1M)(1.31M)1.08M
Inventory(6.46M)(3.64M)918K(229K)(765K)
Accounts Payables87K247K(345K)2.28M270K
Other Working Capital963K(1.48M)(27K)(2.44M)(2.51M)
Other Non-Cash Items11.92M16.8M2.14M2.11M22.33M
Operating Cash Flow(41.43M)(45.14M)(37.61M)(31.54M)(32.45M)
Capital Expenditures(3.67M)(1.32M)(807K)(1.45M)(452K)
Acquisitions (Net)00000
Purchases of Investments(52.58M)(47.19M)(46.2M)(27.91M)(5.65M)
Sales of Investments10M44.28M45M46.84M36.59M
Other Investing Activities00000
Investing Cash Flow(46.26M)(4.23M)(2.01M)17.48M30.48M
Debt Repayment0(87K)19.91M(95K)(100K)
Common Stock Issued4.52M2.59M001M
Common Stock Repurchased(26K)(27K)000
Dividends Paid00000
Other Financing Activities001.49M1.46M0
Financing Cash Flow4.5M2.47M21.4M1.36M903K
Effect of Forex Changes106K145K34K76K(92K)
Net Change in Cash(83.08M)(46.74M)(18.18M)(12.62M)(1.15M)
Free Cash Flow(45.1M)(46.45M)(38.42M)(32.98M)(32.9M)

Pulmonx Corporation

NASDAQ:LUNG

Intrinsic Alpha fair value

Locked

Current Price

$2.69

Margin of safety hidden

Unlock the intrinsic value to see where the current price sits on the valuation runway.

Valuation runway

Locked

Get the intrinsic value and margin of safety with a free account.